Apart from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and match more than enough to tolerate FCR therapy, may still be superior candidates for the latter, While using the benefit remaining that this treatment method is usually completed in 6 months although ibrutinib has to be taken indefinitely. This https://thomase297blt5.mappywiki.com/user